Literature DB >> 17926203

Antibody responses to defined regions of the Bordetella pertussis virulence factor pertactin.

Marcel Hijnen1, Qiushui He, Rutger Schepp, Pieter Van Gageldonk, Jussi Mertsola, Frits R Mooi, Guy A M Berbers.   

Abstract

Although vaccines against Bordetella pertussis, the causative agent of whooping cough, have been in use for over 50 y, the disease has remained endemic and is still a public health problem in many countries. It has been shown that antibody titres against pertactin, which is 1 of the exposed virulence factors of pertussis, correlate with protection and pertactin is now 1 of the components of most acellular pertussis vaccines. However, little is known about the structure and location of protective epitopes on pertactin. Here we set out to investigate the antibody response using naturally occurring pertactin variants and deletion derivates. We found the N-terminus of pertactin to be immunodominant in both rabbits and humans. In contrast to vaccinated rabbits, we could not detect pertactin type-specific antibodies in human sera. In conclusion, these results show for the first time to which defined regions of the pertactin molecule antibody responses are induced. It also suggests that the amount of pertactin type-specific antibodies will not be very large and that the variation in pertactin probably will not constitute a problem in highly immune individuals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17926203     DOI: 10.1080/00365540701642138

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  6 in total

Review 1.  Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.

Authors:  Dorji Dorji; Frits Mooi; Osvaldo Yantorno; Rajendar Deora; Ross M Graham; Trilochan K Mukkur
Journal:  Med Microbiol Immunol       Date:  2017-11-21       Impact factor: 3.402

2.  Functional characterization of AasP, a maturation protease autotransporter protein of Actinobacillus pleuropneumoniae.

Authors:  Tehmeena Ali; Neil J Oldfield; Karl G Wooldridge; David P Turner; Dlawer A A Ala'Aldeen
Journal:  Infect Immun       Date:  2008-10-13       Impact factor: 3.441

Review 3.  Pertussis: Microbiology, Disease, Treatment, and Prevention.

Authors:  Paul E Kilgore; Abdulbaset M Salim; Marcus J Zervos; Heinz-Josef Schmitt
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

4.  Immunodominance in mouse and human CD4+ T-cell responses specific for the Bordetella pertussis virulence factor P.69 pertactin.

Authors:  Rachel M Stenger; Martien C M Poelen; Ed E Moret; Betsy Kuipers; Sven C M Bruijns; Peter Hoogerhout; Marcel Hijnen; Audrey J King; Frits R Mooi; Claire J P Boog; Cécile A C M van Els
Journal:  Infect Immun       Date:  2008-11-17       Impact factor: 3.441

5.  Comparative efficacy of intranasal and injectable vaccines in stimulating Bordetella bronchiseptica-reactive anamnestic antibody responses in household dogs.

Authors:  John A Ellis; Sheryl P Gow; Lindsey B Lee; Stacey Lacoste; Eileen C Ball
Journal:  Can Vet J       Date:  2017-08       Impact factor: 1.008

6.  Bordetella pertussis strains with increased toxin production associated with pertussis resurgence.

Authors:  Frits R Mooi; Inge H M van Loo; Marjolein van Gent; Qiushui He; Marieke J Bart; Kees J Heuvelman; Sabine C de Greeff; Dimitri Diavatopoulos; Peter Teunis; Nico Nagelkerke; Jussi Mertsola
Journal:  Emerg Infect Dis       Date:  2009-08       Impact factor: 6.883

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.